Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study.

ABSTRACT: Acute myeloid leukemia (AML) is a disease affecting older adults, although optimal strategies for treating such patients remain unclear. This prospective phase II, open-label, multicenter study was designed to assess the efficacy and safety of two hematologic growth factors, recombinant human thrombopoietin (rhTPO) and granulocyte colony-stimulating factor (G-CSF), in combination with decitabine, cytarabine, and aclarubicin (D-CTAG regimen) to treat older adults with newly diagnosed AML (Identifier: NCT04168138). The above agents were administered as follows: decitabine (15 mg/m² daily, days 1-5); low-dose cytarabine (10 mg/m² q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, 10-24 or until >50×10⁹/L platelets); aclarubicin (14 mg/m² dail

SUBMITTER: Liu X 

PROVIDER: S-EPMC8485918 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature